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Conclusion: Thus, we have found that metformin significantly
increases the rate of catabolism of adenosine, and this in turn
reduces the inhibitory effect on the tumor microenvironment
cytotoxic cells. Therefore, our data for the first time provide novel
evidence for a mechanism that the anticancer activities of met-
formin are due to adenosine metabolism regulation.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.090
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Background: Human epidermal growth factor receptor-2
(HER2/nue) is overexpressed in breast cancer. It has been shown
that HER2-targeted therapies have radically changed the outcome
of HER2-positive breast cancer patients. The aim of this study was
to develop the technique for preparation of recombinant anti-
HER2/neu antibody from plants and to provide with the basic
characteristics of the HER2/neu oncoprotein.
Materials and Methods: We have designed and synthesized
viral vectors to transform Agrobacterium tumifaciens affinity,
ion exchange and gel filtration chromatography were used to pur-
ify the antibody. The quality of the substance was confirmed by
SDS–PAGE and ELISA. The biological activity was tested by
immunofluorescent analysis.
Results: Antibodies were purified by affinity and ion
exchange chromatography from the Agrobacterium tumifaciens
leaves extracts. Gel filtration chromatography was used for
final purification of the protein. Immunocytochemical staining
was performed to test the functional activity of the plant-
made antibodies. Here we also show that plant-made antibod-
ies bind to HER2/neu receptors on the surface of human
SK-BR-3 breast cancer cells as effectively as the diagnostic
antibody A0485 (DAKO, Denmark). Flow cytometry analysis
was used for quantitative estimation of recombinant anti-
HER2/neu antibodies: from 75.7% to 98.3% cells bound the
plant-made antibodies. The same data were obtained with
trastuzumab.
Conclusion: Based on the data obtained, we conclude that
plant-made antibodies inhibit HER2/neu+ breast cancer cell pro-
liferation. Additional experiments are required to prove that tras-
tuzumab and plant-made antibodies share full identity in their
biological activity.
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Papillary thyroid cancer (PTC) is the most common malig-
nancy of the endocrine system. The most frequent genetic alter-
ation in PTC is the BRAF V600E mutation, which affects the
activation of several intracellular signaling pathways. As a result,
changes in the expression levels of cell membrane integrin
receptors and their ligands – extracellular matrix proteins – osteo-
pontin (OPN) and thrombospondin -1 (TSP1) are observed. This
process increases the metastatic potential of tumor cells. Thus,
integrin receptors and their ligands are potential biomarkers of
an aggressive PTC phenotype.
The aim of our study was to compare the gene expression pro-
file of integrins ITGA2, ITGA3, ITGAV, ITGA6, ITGA9, ITGB1, ITGB3
and their ligands OPNa, OPNb, and TSP1 in PTC with different
BRAF V600E mutation status.
Intraoperative thyroid tissue samples from 41 patients diag-
nosed with PTC (n = 26), diffuse nodular nontoxic goiter (n = 10)
and follicular adenoma (n = 5) were analyzed to evaluate the
expression levels of the investigated genes by real time RT-PCR.
Fluorescent immunohistochemistry (IHC) was used to confirm
the PCR results and to estimate the amount of protein products.
For IHC, frozen and paraffin sections were used. The BRAF
V600E mutation was determined using allele-specific amplifica-
tion. Nonparametric criteria (Kruskal Wallis, Wilcoxon and
Mann–Whitney tests) were used to evaluate group differences. P
values of less than 0.05 were considered statistically significant.
The BRAF V600E mutation was observed in 12 PTC samples,
which corresponds to 46% of PTC cases. An increase of gene
expression level of ITGA3 (2.9-fold, p = 0.014), ITGAV (1.9-fold,
p = 0.038), ITGB1 (1.7-fold, p = 0.026), OPNb (2.5-fold, p = 0.0001)
and TSP1 (3.2-fold, p = 0.017) was identified in the PTC tissues,
and a high gene expression level of OPNb (5.9-fold, p = 0.003)
and TSP1 (12.1-fold, p = 0.005) was identified in the tissue samples
of lymph node metastases compared to the conventionally
normal tissue.
In the samples with advanced cancer (T3, T4, TNM) the
expression levels of ITGA3, ITGA6 and ITGA9 were higher com-
pared to the T1 samples. MRNA levels of ITGA3 and ITGAV were
significantly higher in the PTC BRAF V600E positive samples than
in the BRAF V600E negative samples.
Elevated levels of OPNa (11.4-fold, p = 0.0112), OPNb (10.2-fold,
p = 0.0216) and TSP1 (33.5-fold, p = 0.0005) genes were observed in
the follicular adenoma samples compared to the PTC tissues. For
ITGA2 and ITGB3 there was a significant increase of expression in
the PTC tissues compared to the benign thyroid tumors (8.9-fold,
p = 0.019 and 38.4-fold, p = 0.014, respectively).
We also studied the distribution and localization of integrins
ITGA2 and ITGB3 in the thyroid tissues by IHC. In normal thyroid
tissues ITGA2 and ITGB3 were located mainly in the follicular
membrane. In the PTC tissue samples another location of the
integrins was registered: ITGA2 was located mainly in the
papillary structures, whereas ITGB3 was seen both at the basal
and apical surfaces of thyrocytes. Follicular adenomawas charac-
terized by a uniform distribution of both ITGA2 and ITGB3.
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